 Leland Shapiro
Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| alpha 1-Antitrypsin | 9 | 2015 | 108 | 1.360 |
Why?
| | alpha 1-Antitrypsin Deficiency | 3 | 2013 | 67 | 0.640 |
Why?
| | Shock, Septic | 1 | 2021 | 219 | 0.610 |
Why?
| | HIV Infections | 6 | 2024 | 2836 | 0.500 |
Why?
| | Meningitis, Cryptococcal | 3 | 2024 | 30 | 0.480 |
Why?
| | Sepsis | 1 | 2021 | 617 | 0.460 |
Why?
| | Cryptococcosis | 2 | 2023 | 27 | 0.350 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2021 | 1242 | 0.350 |
Why?
| | Cryptococcus | 2 | 2024 | 11 | 0.350 |
Why?
| | Interleukin-1beta | 3 | 2014 | 372 | 0.340 |
Why?
| | HIV-1 | 3 | 2015 | 864 | 0.300 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 253 | 0.280 |
Why?
| | Interleukin-8 | 1 | 2009 | 268 | 0.280 |
Why?
| | Nitric Oxide | 2 | 2012 | 915 | 0.280 |
Why?
| | Interferon-gamma | 3 | 2007 | 789 | 0.270 |
Why?
| | Mycobacteriaceae | 1 | 2007 | 24 | 0.260 |
Why?
| | Receptors, CXCR4 | 1 | 2007 | 86 | 0.260 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 363 | 0.250 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2007 | 141 | 0.240 |
Why?
| | Interleukin-18 | 1 | 2007 | 236 | 0.240 |
Why?
| | Interleukin-10 | 1 | 2007 | 302 | 0.230 |
Why?
| | Cryptococcus neoformans | 1 | 2024 | 21 | 0.220 |
Why?
| | Anti-HIV Agents | 2 | 2007 | 778 | 0.210 |
Why?
| | Macrophages | 2 | 2012 | 1547 | 0.210 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 127 | 0.200 |
Why?
| | Antigens, Fungal | 2 | 2024 | 28 | 0.180 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 186 | 0.170 |
Why?
| | Cytokines | 4 | 2021 | 2085 | 0.160 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 36 | 0.160 |
Why?
| | Medical Errors | 1 | 2020 | 112 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1091 | 0.130 |
Why?
| | Patient Safety | 1 | 2020 | 314 | 0.130 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2008 | 64 | 0.130 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 740 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1050 | 0.120 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2015 | 18 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Adult | 12 | 2024 | 37929 | 0.110 |
Why?
| | Virus Activation | 1 | 2015 | 88 | 0.110 |
Why?
| | Research Design | 1 | 2021 | 1139 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Humans | 21 | 2024 | 137585 | 0.110 |
Why?
| | Intraabdominal Infections | 1 | 2014 | 11 | 0.110 |
Why?
| | Middle Aged | 10 | 2018 | 33479 | 0.110 |
Why?
| | Virus Replication | 2 | 2021 | 483 | 0.110 |
Why?
| | Mycoses | 1 | 2014 | 79 | 0.100 |
Why?
| | RNA, Viral | 2 | 2021 | 656 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2014 | 148 | 0.100 |
Why?
| | NF-kappa B | 2 | 2015 | 691 | 0.100 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2012 | 173 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2013 | 2426 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Dendritic Cells, Follicular | 1 | 2011 | 5 | 0.090 |
Why?
| | Male | 13 | 2018 | 67762 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2012 | 313 | 0.090 |
Why?
| | Monocytes | 1 | 2014 | 563 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 350 | 0.090 |
Why?
| | Phosphorylation | 2 | 2012 | 1759 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2012 | 810 | 0.090 |
Why?
| | Emphysema | 1 | 2011 | 106 | 0.090 |
Why?
| | I-kappa B Proteins | 1 | 2011 | 81 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2014 | 483 | 0.080 |
Why?
| | Female | 13 | 2018 | 73304 | 0.080 |
Why?
| | Epoprostenol | 1 | 2010 | 136 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2531 | 0.080 |
Why?
| | Blood Cells | 1 | 2009 | 40 | 0.080 |
Why?
| | Risk Factors | 5 | 2024 | 10388 | 0.070 |
Why?
| | Staphylococcus epidermidis | 1 | 2009 | 77 | 0.070 |
Why?
| | Physical Endurance | 1 | 2010 | 275 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 852 | 0.070 |
Why?
| | Islets of Langerhans | 1 | 2014 | 803 | 0.070 |
Why?
| | Placebos | 1 | 2007 | 199 | 0.070 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2007 | 47 | 0.070 |
Why?
| | Cell Line | 1 | 2012 | 2847 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2008 | 363 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2010 | 1993 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 494 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2014 | 3715 | 0.060 |
Why?
| | Transplantation Tolerance | 1 | 2005 | 36 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4193 | 0.060 |
Why?
| | Aged | 6 | 2018 | 23961 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2475 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2018 | 3556 | 0.050 |
Why?
| | Phenotype | 2 | 2012 | 3196 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2553 | 0.050 |
Why?
| | Propensity Score | 1 | 2023 | 294 | 0.050 |
Why?
| | History, 17th Century | 1 | 2020 | 16 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2024 | 594 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 213 | 0.040 |
Why?
| | Mice | 3 | 2012 | 17787 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 5472 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 325 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1910 | 0.040 |
Why?
| | Mortality | 1 | 2020 | 362 | 0.030 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.030 |
Why?
| | Animals | 4 | 2012 | 36940 | 0.030 |
Why?
| | Cohort Studies | 1 | 2007 | 5742 | 0.030 |
Why?
| | Inflammation | 1 | 2007 | 2837 | 0.030 |
Why?
| | Hospitals, University | 1 | 2016 | 182 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1316 | 0.030 |
Why?
| | Clathrin | 1 | 2015 | 27 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 6828 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2018 | 15657 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 7604 | 0.030 |
Why?
| | Lysosomes | 1 | 2015 | 141 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 512 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2016 | 202 | 0.030 |
Why?
| | Cytosol | 1 | 2015 | 226 | 0.030 |
Why?
| | Hearing Loss | 1 | 2018 | 221 | 0.030 |
Why?
| | Endocytosis | 1 | 2015 | 172 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2014 | 30 | 0.030 |
Why?
| | Endosomes | 1 | 2015 | 136 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1509 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 565 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 13209 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2014 | 136 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 185 | 0.030 |
Why?
| | Funnel Chest | 1 | 2012 | 27 | 0.020 |
Why?
| | Peritoneal Dialysis | 1 | 2014 | 97 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2074 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 49 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2031 | 0.020 |
Why?
| | Gene Frequency | 1 | 2013 | 521 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 53 | 0.020 |
Why?
| | PPAR alpha | 1 | 2011 | 58 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 56 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 657 | 0.020 |
Why?
| | Polyubiquitin | 1 | 2011 | 6 | 0.020 |
Why?
| | Lung Diseases | 1 | 2018 | 767 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 132 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2011 | 54 | 0.020 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2011 | 26 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 152 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2734 | 0.020 |
Why?
| | Ubiquitination | 1 | 2011 | 102 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 347 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 246 | 0.020 |
Why?
| | Transcription Factor RelA | 1 | 2011 | 87 | 0.020 |
Why?
| | PPAR gamma | 1 | 2011 | 182 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 141 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2011 | 239 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 215 | 0.020 |
Why?
| | RNA Interference | 1 | 2011 | 469 | 0.020 |
Why?
| | Adolescent | 3 | 2014 | 21513 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 413 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 405 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 545 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1295 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2014 | 570 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 635 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 843 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 416 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2014 | 10811 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2008 | 5757 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4565 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2008 | 491 | 0.020 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2005 | 11 | 0.020 |
Why?
| | Chemokine CCL3 | 1 | 2005 | 16 | 0.020 |
Why?
| | Chemokine CCL4 | 1 | 2005 | 23 | 0.020 |
Why?
| | Granulocytes | 1 | 2005 | 80 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 2005 | 200 | 0.010 |
Why?
| | Walking | 1 | 2010 | 529 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 7635 | 0.010 |
Why?
| | Cell Movement | 1 | 2008 | 967 | 0.010 |
Why?
| | Body Mass Index | 1 | 2012 | 2389 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2005 | 367 | 0.010 |
Why?
| | Child | 2 | 2014 | 21935 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3412 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5647 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2005 | 449 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2828 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2005 | 965 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4295 | 0.010 |
Why?
| | Heart Failure | 1 | 2014 | 2236 | 0.010 |
Why?
| | United States | 1 | 2018 | 14841 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 1040 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2607 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 4149 | 0.010 |
Why?
| | Exercise | 1 | 2010 | 2057 | 0.010 |
Why?
|
|
Shapiro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|